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Aims: TECOS, a cardiovascular safety trial (ClinicalTrials.gov identifier: NCT00790205) involv-
ing 14 671 patients with type 2 diabetes and cardiovascular disease, demonstrated that sita-
gliptin was non-inferior to placebo for the primary composite cardiovascular outcome when
added to best usual care. This study tested hypotheses that medical resource use and costs dif-
fered between these 2 treatment strategies.
Materials and methods: Information concerning medical resource use was collected on case
report forms throughout the trial and was valued using US costs for: Medicare payments for
hospitalizations, medical procedures and outpatient visits, and wholesale acquisition costs
(WAC) for diabetes-related medications. Hierarchical generalized linear models were used to
compare resource use and US costs, accounting for variable intercountry practice patterns.
Sensitivity analyses included resource valuation using English costs for a UK perspective.
Results: There were no significant differences in hospitalizations, inpatient days, medical proce-
dures, or outpatient visits during follow-up (mean and median 3.0 years in both groups). Hospi-
talization rates appeared to diverge after 2 years, with lower rates among sitagliptin-treated vs
placebo patients after 2.5 years (relative rate, 0.90 [95% CI, 0.83-0.97]; P = .01). Mean medical
costs, exclusive of study medication, were 11 937 USD in the sitagliptin arm and 12 409 USD
in the placebo arm (P = .06). Mean sitagliptin costs based on undiscounted WAC were 9978
USD per patient. Differential UK total costs including study drug costs were smaller (911 GBP),
primarily because of lower mean costs for sitagliptin (1072 GBP).
Conclusions: Lower hospitalization rates across time with sitagliptin slightly offset sitagliptin
treatment costs over 3 years in type 2 diabetes patients at high risk for cardiovascular events.
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1 | INTRODUCTION
The economic implications of type 2 diabetes are immense.
Disability-adjusted life-years associated with diabetes increased
globally by 29% between 2005 and 2015.1 Estimated global health
expenditures for diabetes ranged from 612 billion USD to 1.10 tril-
lion USD per year in 2014.2 These extraordinary numbers are
expected to grow as the number of individuals with diabetes world-
wide is projected to rise from 415 million in 2015 to 642 million by
2040.3†These authors contributed equally.
Patients with type 2 diabetes have rates of coronary heart dis-
ease and ischemic stroke that are 2-fold higher than those of patients
without type 2 diabetes, even after adjusting for traditional risk fac-
tors.4 Although there is evidence of long-term declines in the excess
risk of death and cardiovascular outcomes in individuals with type
2 diabetes,5 death rates with vascular causes and non-vascular
causes, including cancer and infectious diseases, remain significantly
higher among individuals with type 2 diabetes.6 Numerous therapeu-
tic strategies are available to improve glycaemic control, with the goal
of reducing morbidity and mortality, but questions about potential
adverse effects on major cardiovascular events have been raised,7,8
leading regulators to require large-scale cardiovascular safety trials of
new treatments for type 2 diabetes.9,10 These trials typically strive
for equivalent levels of glycaemic control between study arms to iso-
late the potential direct impact of the study drug on major adverse
cardiovascular events from possible indirect effects attributable to
better glycaemic control.
The Trial Evaluating Cardiovascular Outcomes with Sitagliptin
(TECOS), a placebo-controlled cardiovascular safety study, was
designed to test the impact of adding sitagliptin, a dipeptidyl
peptidase-4 (DPP-4) inhibitor, to usual care in patients with type
2 diabetes and established cardiovascular disease who did not receive
other DPP-4 inhibitors or glucagon-like peptide-1 (GLP-1) receptor
agonists.11 A prespecified secondary objective was to compare medi-
cal resource use during the trial by treatment arm. As an extension,
we valued all medical resources using US cost weights and compared
direct medical costs between study arms. As a sensitivity analysis, we
also valued medical resources using UK cost weights, to evaluate the
results in a different setting.
2 | RESEARCH DESIGN AND METHODS
2.1 | TECOS trial design and results
Eligible patients had a history of cardiovascular disease. Baseline gly-
cated haemoglobin (HbA1c) range for enrollment was 6.5% to 8.0%
(48-64 mmol/mol). Patients were randomized to either placebo or
sitagliptin (100 or 50 mg daily, depending on renal function). The
primary endpoint was time to first cardiovascular-related death, non-
fatal myocardial infarction, non-fatal stroke or hospitalization for
unstable angina. The study was powered to demonstrate non-
inferiority of sitagliptin added to usual care vs usual care alone, with
90% power to exclude a 30% increased risk of cardiovascular events
with sitagliptin-based care.11 The protocol for the study was
approved by the ethics committees associated with all participating
trial sites, and all participants provided written informed consent.
In TECOS, the intention-to-treat analysis population included
14 671 randomized participants from 38 countries. Participants in
both study groups were followed for a mean of 3.0 years (sitagliptin,
3.01 [SD, 0.96]; placebo, 2.99 [SD, 0.97]).12 Approximately one-
quarter of participants in both arms discontinued study medication
prior to the end of follow-up (sitagliptin, 26.1%; placebo, 27.5%).
Despite the aim of equal glycaemic control between groups, mean
HbA1c levels were, on average, 0.3% lower with sitagliptin (95%
confidence interval [CI], −0.32 to −0.27). Sitagliptin was shown to be
non-inferior to placebo for the primary composite cardiovascular out-
come (hazard ratio [HR], 0.98; 95% CI, 0.88–1.09; P for non-inferiority
<.001). All-cause mortality was similar in both arms (HR, 1.01; 95%
CI, 0.90-1.14). The proportion of patients initiating insulin during the
trial was significantly lower in the sitagliptin group (9.7%) compared
to the placebo group (13.2%; P < .001). Severe hypoglycaemia
occurred in 2.0% of patients randomized to sitagliptin compared with
1.7% of patients randomized to placebo (HR, 1.13; 95% CI,
0.89-1.44).
2.2 | Economic evaluation
Academic health economics teams from the Duke Clinical Research
Institute and the University of Oxford Health Economics Research
Centre led and performed the economic evaluation. An analysis plan,
finalized on August 7, 2015, was used to guide cost assignment and
planned statistical analysis.
2.3 | Medical resource use and cost assignment
Data on medical resource use, including hospitalizations, cardiovascu-
lar procedures, study visits, outpatient visits to usual diabetes care
providers or other providers, concomitant medications, and study
drug were collected at 4, 8, and 12 months, and then every 6 months
through to study end.
For each hospitalization, admission and discharge dates were
recorded, along with the primary discharge diagnosis documented as
1 of 32 prespecified diagnoses or free text. All major cardiovascular
and renal procedures were recorded, as were specific procedures for
management of congestive heart failure, cardiac ischaemic event,
stroke/transient ischaemic attack and pancreatitis.
Numbers of treatment days on study drugs were derived from
trial records, accounting for intermittent discontinuations. Informa-
tion for other diabetes medicines included drug name and daily dose,
but start and stop dates were not collected, hence drug use recorded
as “yes” was assumed to continue until “no” was recorded at a subse-
quent visit.
2.4 | Cost assignment
Costs were assigned to medical resource use reported for all patients
in the trial. US hospital cost assignment was based on Medicare reim-
bursement rates for corresponding Diagnosis-Related Group (DRG)
codes assigned to prespecified discharge diagnoses and procedures
(Tables S1 and S2 in File S1) and high-frequency free-text discharge
diagnoses recorded in TECOS. To account for systematic differences
in length of stay across patients in different countries with the same
diagnosis, we applied an approach to inpatient cost assignment used
in another large multinational trial.13 For each DRG code, cost per
inpatient day was estimated by dividing the 2015 Medicare reim-
bursement by the median length of stay published by the Centers for
Medicare and Medicaid Services,14 then merged with hospitalizations
using the assigned DRG code. We then adjusted lengths of stay
recorded for hospitalizations outside the USA to approximate the
length of stay had the patient been treated at a US facility. This was
done by calculating the ratio of mean length of stay across all hospi-
talizations in the USA to the mean length of stay in each non-US
country participating in TECOS. The resulting country-specific ratio
was multiplied by the length of stay for each hospitalization record
and the DRG-specific daily inpatient cost.
The 2015 Medicare Physician Fee Schedule was used to estimate
costs for physician services using Current Procedural Terminology
codes (Tables S3 and S4 in File S1).15 Daily costs for concomitant dia-
betes medications were provided by Merck & Co., Inc., based on
2015 wholesale acquisition costs (WAC) published by First Databank,
which represent the manufacturer's published list price to wholesalers
and may not represent actual transactional prices.16 As generic drugs
were available from multiple manufacturers, the lowest and highest
costs for specific daily doses of concomitant diabetes drugs were
developed. Lowest costs for generic drugs were used in the base-
case analysis. The daily cost assigned for sitagliptin was 11.02 USD
across all doses. All costs incurred beyond the first year were dis-
counted at 3% per year.
2.5 | Statistical analysis
Descriptive statistics, including proportions, means, standard devia-
tions and medians, summarized counts of medical resource use and
costs by treatment group. Mean cumulative counts of hospitalizations
per patient that account for censoring across time were plotted,17
and annual hospitalization rates were computed by dividing the total
number of hospitalizations for each treatment group in each year by
the total duration of follow-up in the corresponding year.
To account for the nested structure of the multinational trial
data, generalized linear mixed models were used to compare counts
of medical resource use between treatment groups using SAS's
PROC GLIMMIX with Laplace estimation (SAS Institute, Version
9.4). The models included treatment assignment as the independent
variable, with the log of each participant's duration of follow-up as
an offset variable to adjust for differences in observation time.
Treatment assignment was modeled as a fixed effect and countries
were modeled as random intercepts, to allow rates of medical
resource use and costs in the placebo group to vary across coun-
tries while modeling the relative impact of sitagliptin as a fixed
effect across countries. To compare medical resource use counts
(hospitalizations, inpatient days and outpatient visits), the models
were specified with negative binomial error distributions and log
links. Models to compare diabetes drug-days relied on normal distri-
butions and identity links. For cost comparisons, gamma error distri-
butions and log links were used. The exponentiated parameter
estimates from these models represent relative rates (RR) for
resource use and means ratios for costs. To provide additional
descriptive information about treatment effects on resource use and
costs on an absolute scale, differences in mean counts were
computed and corresponding 95% CIs were estimated using the
bias-corrected percentile method based on 1000 non-parametric
bootstrap replications.18
2.6 | Sensitivity analysis
Several sensitivity analyses were performed to evaluate the impact
of alternative methods and assumptions on study findings. First, in
lieu of assigning the lowest WACs reported for generic diabetes
medications, the highest WACs were assigned. Second, when adjust-
ing lengths of stay for hospitalizations outside the USA, we calcu-
lated the conversion ratios using median rather than mean lengths
of stay. Third, we replicated the entire analysis using costs from the
UK rather than the USA (see Suporting Information Methods for
details).
2.7 | Subgroup analysis
Subgroup analyses were performed to determine whether adding
sitagliptin to usual care had a differential impact on all-cause hospital-
izations. Selection of subgroups mirrored those that were prespeci-
fied or conducted for the primary clinical endpoint.12
2.8 | Post-hoc analysis
Post-hoc analyses were performed to compare rates of hospitaliza-
tions between groups among patients with longer periods of
follow-up.
3 | RESULTS
Participants randomized to receive sitagliptin in addition to usual care
were hospitalized 4803 times compared with 5168 times among par-
ticipants randomized to receive placebo (Figure 1), representing
34.1% and 34.6% of participants, respectively (P = .26), being hospi-
talized at least once over the 3-year follow-up period. The mean
number of hospitalizations was 0.66 in the sitagliptin arm and 0.70 in
the placebo arm (RR, 0.95 [95% CI, 0.90-1.02] P = .14) (Figure 1).
Mean number of inpatient days was 5.50 days for the sitagliptin
group and 5.74 days for the placebo group (P = .94) (Table 1). Mean
count of outpatient visits was 19.4 per participant in both groups
(P = .85). Mean number of concomitant diabetes drug-days was 1635
FIGURE 1 Mean cumulative number of hospitalizations per patient
and 95% confidence intervals by treatment group (see Table 3 for
results by minimum follow-up duration)
and 1673 per participant for the sitagliptin and placebo groups,
respectively, or approximately 1.5 diabetes drugs per day per partici-
pant (P = .06). When including sitagliptin, diabetes drug-days aver-
aged 2.3 per day per participant among those randomized to the
sitagliptin arm. Mean number of days on insulin therapy was 234 per
participant in the sitagliptin arm compared to 241 days in the placebo
arm (P = .26).
Inpatient costs over the follow-up period averaged 6947 USD in
the sitagliptin arm and 7377 USD in the placebo arm (Table 1). Out-
patient care costs were approximately 1465 USD in both study
groups. Mean total costs for medical resources, exclusive of sitaglip-
tin, were 11 937 USD in the sitagliptin arm and 12 409 USD in the
placebo arm. Mean costs for sitagliptin were estimated at 9978 USD,
resulting in total within-trial costs for the sitagliptin group of
21 915 USD.
3.1 | Sensitivity analysis
When concomitant diabetes medicines were assigned the upper
(rather than lower) bound of prices across generic manufacturers, dia-
betes medications costs averaged 4126 USD in the sitagliptin arm vs
4198 USD in the placebo arm, a difference of 72 USD. Using length-
of-stay conversion ratios based on median (rather than mean) length
of stay in the USA relative to other countries, estimated inpatient
costs were 901 USD higher in the sitagliptin arm and 931 USD higher
in the placebo arm. And, when resource use was valued using UK
costs, inpatient costs over the follow-up period averaged 2629 GBP
in the sitagliptin arm and 2760 GBP in the placebo arm (Table 1).
Outpatient care costs were 2648 GBP in the sitagliptin arm and 2654
GBP in the placebo arm. Mean total costs for medical resources,
exclusive of sitagliptin, were £6058 in the sitagliptin arm and 6219
GBP in the placebo arm. Mean costs for sitagliptin were estimated at
1072 GBP, resulting in total within-trial costs for the sitagliptin arm
of 7130 GBP, which was 911 GBP higher than those for the placebo
arm (P < .001).
3.2 | Subgroup analysis
Effects of sitagliptin on hospitalizations by subgroup are reported in
Table 2. Only 1 interaction term was statistically significant at
P < .05, suggesting that younger patients (<75 years of age) may
experience fewer hospitalizations when treated with sitagliptin.
Within subgroups, only 1 P value was <.05, occurring among patients
with diabetes duration of 5 to <15 years.
3.3 | Post-hoc analysis
Post-hoc analyses revealed that patients with at least 2.5 years of
follow-up experienced a 10% lower rate of hospitalization (ie, RR,
0.90; P = .01) when treated with sitagliptin compared to placebo
(Table 3). This observation was maintained among smaller groups of
patients with at least 3.0 and 3.5 years of follow-up.
4 | DISCUSSION
TECOS randomized 14 671 patients across 38 countries to evaluate
long-term safety of sitagliptin in patients with type 2 diabetes and
pre-existing cardiovascular disease. Clinical findings confirmed that
sitagliptin, when added to usual care (but excluding DPP-4 inhibitors
and GLP-1 receptor agonists), is non-inferior to placebo plus usual
care with regard to its impact on cardiovascular outcomes, including
cardiovascular death, non-fatal myocardial infarction, non-fatal stroke,
and hospitalization for unstable angina, and had no impact on the
incidence of hospitalization for heart failure.19
The TECOS trial allowed providers to help enrolled patients
achieve individualized glycaemic control goals with their choice of
open-label antihyperglycaemic agents, excluding other DPP-4 inhibi-
tors or GLP-1 receptor agonists and, as a randomized and blinded
clinical trial, permits an internally valid evaluation of whether the
addition of sitagliptin had an independent impact on medical resource
use and associated costs. However, it should be noted that not all
resources of relevance in type 2 diabetes (such as glucose testing
strips) were measured. In addition, despite the aim of achieving gly-
caemic equipoise, participants randomized to sitagliptin had mean
HbA1c values 0.3% lower, on average, than those of the placebo arm,
suggesting possible suboptimal addition of antihyperglycaemic agents
in the control arm during the study, and commensurately lower medi-
cation costs in that arm than if equal glycaemic control had been
achieved. The study design also limited enrollment to participants
with HbA1c levels of 6.5% to 8.0% at baseline, potentially restricting
the opportunity to demonstrate effects of improved glycaemic con-
trol, which may have reduced the generalizability of our findings.
Drug costs, monitoring costs and costs to manage drug-related
side effects are essential components of an economic evaluation of
sitagliptin. In our resource utilization study, we observed slightly
fewer drug treatment days with concomitant diabetes drugs and
fewer days on insulin in the sitagliptin arm, but little cost saving
because of the low cost of generic diabetes drugs and the modest
absolute differences in total insulin use between arms, given the pro-
portion of patients (23%) using insulin at study entry. At the outset
of the trial, we considered that sitagliptin might make it easier to
achieve personalized glucose targets and reduce the number of out-
patient visits relative to usual care plus placebo, but in practice, the
mean number of outpatient visits reported was nearly identical. How-
ever, it is possible that additional care for drug initiation or monitor-
ing occurred during protocol-required visits that was not captured in
the context of the TECOS trial, which may have reduced the oppor-
tunity to observe additional differences in resource utilization
between arms.
The 0.3% lower HbA1c values in the sitagliptin arm may have
contributed to several indications that the treatment lowered hospi-
talization rates. The 95% CI corresponding to the difference in mean
hospitalizations between treatment arms excluded zero, consistent
with a nominally significant finding at P < .05, but the P value from
the prespecified hierarchical model to compare hospitalization rates
in the primary analysis was not statistically significant. We also
observed cases where mean costs in the sitagliptin arm were lower
than those in the placebo arm, yet means ratios were consistent with
higher costs. These inconsistencies can be attributed to the
resampling-with-replacement procedure employed with the standard
approach to bootstrapping, whereas the modeling procedure
accounts for correlations across patients enrolled within a country
and adjusts for patient-level differences in duration of follow-up.
More compelling evidence is that all-cause hospitalization rates
began to diverge in the second year of follow-up and continued
through the fifth year. Evidence from previous long-term trials in dia-
betes suggests that changes in HbA1c require long follow-up periods
to observe cardiovascular benefits, and it has been hypothesized that
a “metabolic memory” may contribute to such effects.20,21 Post-hoc
analyses suggest that hospitalization rates were approximately 10%
lower among patients treated with sitagliptin. The net clinical and
economic impact is dependent on the absolute hospitalization rate,
which was 0.24 per patient-year for the placebo group, but varied
widely across countries, ranging (in countries with ≥100 patients per
arm) from 0.06 per patient-year in India to 0.57 per patient-year in
New Zealand. The hospitalization rate for the placebo arm in the
USA, where more than 1000 patients were randomized to placebo,
was 0.34 per patient-year. At 10 000 USD per hospitalization, a 10%
reduction in hospitalizations would result in savings of 335 USD per
patient-year in the USA. By comparison, the annual cost of sitagliptin,
based on the WAC, was estimated at approximately 3300 USD. Dis-
counts and rebates negotiated by payers are not transparent, but a
recent report from the US Office of the Inspector General reports a
mean rebate of 23.1% of the average manufacturer's price for
brand-name drugs paid for by Medicaid.22 With this discount, treat-
ment costs of approximately 2500 USD would be marginally offset
with lower inpatient costs. In other jurisdictions, with higher rates
of hospital admission and/or larger discounts and rebates for sita-
gliptin, the offset could be larger. In the UK cost analysis, lower
annual costs of sitagliptin treatment (relative to the USA), combined
with savings in hospitalization costs (relative to the placebo group),
reduced total incremental costs to approximately 300 GBP per
patient-year.
The present study is a resource utilization study conducted
within a clinical trial and cannot be compared directly with cost-
effectiveness analyses of sitagliptin, which typically estimate incre-
mental lifetime costs and quality-adjusted life-years (QALYs) as the
outcome measure. Previously published cost-effectiveness analyses
have suggested that, when sitagliptin is compared with sulfonylureas
in patients receiving metformin monotherapy, lifetime gains with
use of sitagliptin range from 0.04 to 0.1 QALYs.23 Using the upper
end of that range, incremental lifetime costs with use of sitagliptin
less than 10 000 USD would maintain an incremental cost-
effectiveness ratio of <100 000 USD per QALY. In a UK setting,
lifetime costs with use of sitagliptin would have to be less than
2000 GBP to maintain an incremental cost-effectiveness ratio of
<20 000 GBP per QALY.
TABLE 1 Medical resource use and costs throughout trial
Sitagliptin (n = 7332) Placebo (n = 7339) Difference (95% CI)a
Relative rate/means ratio
(95% CI) P value
Medical resource use
All-cause hospitalizations 0.66 (1.29) 0.70 (1.43) −0.05 (−0.09 to −0.01) 0.95 (0.90-1.02) .14
Inpatient days 5.50 (16.38) 5.74 (16.54) −0.24 (−0.77 to 0.24) 1.00 (0.90-1.10) .94
Outpatient care visits 19.42 (17.36) 19.43 (17.35) −0.01 (−0.52 to 0.58) 1.00 (0.98-1.02) .85
Diabetes drug-daysb 1635 (833) 1673 (861) −38 (−66 to −11) 0.99 (0.97-1.00) .06
Direct medical costsc (USD, 2015)
Inpatient care 6947 (19 935) 7377 (20 066) −430 (−1109 to 168) 1.08 (0.97-1.21) .17
Outpatient care 1465 (1413) 1464 (1364) 1 (−39 to 50) 1.00 (0.97-1.03) .88
Diabetes medications 3524 (7644) 3567 (7623) −43 (−269 to 216) 0.96 (0.91-1.02) .18
Total, excluding sitagliptin 11 937 (22 265) 12 409 (22 283) −472 (−1193 to 247) 1.04 (1.00-1.09) .06
Sitagliptin 9978 (4527) 0 (0)
Total costs 21 915 (22 630) 12 409 (22 283) 9506 (8809 to 10 233) 1.79 (1.73-1.86) <.001
Direct medical costsd
(English GBP, 2015)
Inpatient care 2629 (19 935) 2760 (20 066) −131 (−406 to 116) 1.05 (0.94-1.17)e .20
Outpatient care 2648 (2287) 2654 (2294) −6 (−73 to 73) 1.00 (0.97-1.03) .94
Diabetes medications 781 (870) 805 (868) −24 (−50 to −5) 0.99 (0.96-1.02) .38
Total, excluding sitagliptin 6058 (8769) 6219 (9061) −161 (−445 to 119) 1.02 (0.99-1.05) .22
Sitagliptin 1072 (485) 0 (0)
Total costs 7130 (8822) 6219 (9061) 911 (627 to 1201) 1.19 (1.16-1.23) <.0001
Data are given as mean (SD) unless otherwise indicated.
a 95% CIs based on bias-adjusted percentile method with non-parametric bootstrapping.
b Represents the number of diabetes drugs per day summed across the follow-up period for each patient.
c Costs discounted at 3% per annum.
d Costs discounted at 3.5% per annum.
e Rate ratio, 95%CIs, and P-value estimated using Stata's MEGLM command.
Our findings raise some methodological issues associated with
conducting economic evaluations using data from multinational clini-
cal trials. First, assigning costs to medical resource use in such trials is
complex.24–26 We applied a pragmatic approach, assigning US-based
costs to medical resources used by patients from all countries, but
adjusting inpatient length of stay to account for variations in practice
patterns. We also applied UK costs in a sensitivity analysis to evalu-
ate the impact of different price weights on the results. However, all
approaches must recognize that practice patterns, and thus rates of
medical resource use, can vary dramatically across jurisdictions. We
also realize that the constraints of excluding GLP-1 receptor agonists
and other DPP-4 inhibitors from usual care means that the results
may be less generalizable to countries where these drugs are treat-
ment options.
The TECOS trial provides valuable large-scale pragmatic insights
into the short- to mid-term incremental effects on medical resource
use and costs when sitagliptin is added to usual care for type 2 diabe-
tes patients with cardiovascular disease. We observed small reduc-
tions in insulin use and hospitalization rates when sitagliptin was
added to usual care. These cost-savings slightly offset sitagliptin
treatment costs over a 3-year period. The amount of drug cost offset
in the USA would be proportionately larger, with greater discounts
and rebates on the WAC for sitagliptin. As type 2 diabetes is a
chronic, progressive and complex disease, further research is needed
TABLE 2 Impact of sitagliptin on all-cause hospitalizations by subgroup







Agec <65 y 6616 0.92 (0.83-1.02) .11 .36d
≥65 y 7735 0.98 (0.91-1.06) .65
<75 y 12 347 0.93 (0.87-1.00) .05 .04d
≥ 75 y 2004 1.09 (0.95-1.26) .23
Sexc Male 10 374 0.96 (0.90-1.04) .33 .53
Female 4297 0.94 (0.83-1.05) .26
Body mass index < 30 kg/m2 7735 1.00 (0.91-1.09) .91 .21d
≥ 30 kg/m2 6799 0.92 (0.84-1.00) .06
Duration of diabetesc < 5 y 2858 0.96 (0.82-1.13) .66 .23d
5–<15 y 7511 0.91 (0.83-0.99) .03
≥15 y 4290 1.02 (0.91-1.13) .77
Prior congestive heart
failure
Yes 2643 0.99 (0.87-1.12) .87 .42
No 12 028 0.94 (0.88-1.01) .08
Insulin therapy at baselinec Yes 3408 0.96 (0.86-1.08) .48 .63
No 11 263 0.94 (0.88-1.01) .12
Geographic region Asia Pacific and
other
4565 0.98 (0.88-1.11) .78 .53
Eastern Europe 3965 0.92 (0.82-1.04) .18
Latin America 1471 1.13 (0.89-1.43) .33
North America 2594 0.90 (0.79-1.03) .13
Western Europe 2076 0.96 (0.82-1.12) .61
a P values for treatment assignment for each subgroup.
b P values for interactions between treatment arm and categorical subgroup.
c Prespecified subgroups in trial protocol.
d P values for interaction terms for interactions between treatment group and continuous, linear variables representing are .32 for age, .07 for body mass
index, and .18 for duration of diabetes.
TABLE 3 Hospitalization rates and relative impact of sitagliptin on all-cause hospitalizations by minimum follow-up duration
Unadjusteda Adjustedb
Duration of follow-up (y) N Sitagliptin Placebo Relative rate Relative rate P valueb
≥ 2 13 700 0.203 0.223 0.91 0.94 (0.88-1.01) .07
≥ 2.5 9674 0.200 0.227 0.88 0.90 (0.83-0.97) .01
≥ 3 7189 0.199 0.225 0.88 0.90 (0.83-0.98) .02
≥ 3.5 4440 0.183 0.213 0.86 0.89 (0.79-0.99) .03
≥ 4 2641 0.186 0.215 0.86 0.89 (0.77-1.02) .10
a Number of hospitalizations divided by patient-years of follow-up in each time interval.
b Adjusted relative rate and P values from SAS GLIMMIX procedure representing relative impact of sitagliptin vs placebo, accounting for country-level
correlation and adjusted for age, sex, prior CV disease and years since diabetes diagnosis.
concerning the impact of DPP-4 inhibitor treatment on clinical out-
comes, health care resource utilization and costs in broader diabetes
populations such as those with higher HbA1c levels, with and without
pre-existing cardiovascular disease.
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